These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22985853)

  • 1. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
    Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
    Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.
    Zhao A; Gao X; Wang Y; Ai J; Wang Y; Chen Y; Geng M; Zhang A
    Bioorg Med Chem; 2011 Jul; 19(13):3906-18. PubMed ID: 21665484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
    Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
    Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
    Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
    Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase.
    Porter J; Lumb S; Lecomte F; Reuberson J; Foley A; Calmiano M; le Riche K; Edwards H; Delgado J; Franklin RJ; Gascon-Simorte JM; Maloney A; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 Jan; 19(2):397-400. PubMed ID: 19059779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
    Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
    Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
    Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
    Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
    Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
    Milkiewicz KL; Aimone LD; Albom MS; Angeles TS; Chang H; Grobelny JV; Husten J; Losardo C; Miknyoczki S; Murthy S; Rolon-Steele D; Underiner TL; Weinberg LR; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem; 2011 Nov; 19(21):6274-84. PubMed ID: 21967808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.